A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

  1. Castroviejo-Bermejo, M.
  2. Cruz, C.
  3. Llop-Guevara, A.
  4. Gutiérrez-Enríquez, S.
  5. Ducy, M.
  6. Ibrahim, Y.H.
  7. Gris-Oliver, A.
  8. Pellegrino, B.
  9. Bruna, A.
  10. Guzmán, M.
  11. Rodríguez, O.
  12. Grueso, J.
  13. Bonache, S.
  14. Moles-Fernández, A.
  15. Villacampa, G.
  16. Viaplana, C.
  17. Gómez, P.
  18. Vidal, M.
  19. Peg, V.
  20. Serres-Créixams, X.
  21. Dellaire, G.
  22. Simard, J.
  23. Nuciforo, P.
  24. Rubio, I.T.
  25. Dientsmann, R.
  26. Barrett, J.C.
  27. Caldas, C.
  28. Baselga, J.
  29. Saura, C.
  30. Cortés, J.
  31. Déas, O.
  32. Jonkers, J.
  33. Masson, J.-Y.
  34. Cairo, S.
  35. Judde, J.-G.
  36. O'Connor, M.J.
  37. Díez, O.
  38. Balmaña, J.
  39. Serra, V.
  40. Show all authors +
Journal:
EMBO Molecular Medicine

ISSN: 1757-4684,  1757-4676

Year of publication: 2018

Volume: 10

Issue: 12

Type: Article

DOI: 10.15252/EMMM.201809172 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus